2025年核酸药物品牌推荐：技术迭代浪潮下的创新领航者

Investment Rating - The report indicates a positive investment outlook for the nucleic acid drug industry, anticipating it to become the third major category of drugs, driven by technological innovation and increased capital investment [5]. Core Insights - Nucleic acid drugs are emerging as a new therapeutic approach with high efficiency and low toxicity, particularly in rare diseases, and are expanding into common diseases. The global market for nucleic acid drugs is rapidly growing, supported by expanded indications, policy backing, and research collaborations [5]. - The nucleic acid drug market size grew from 18.816 billion RMB in 2019 to 155.828 billion RMB in 2023, with a compound annual growth rate (CAGR) of 69.64%. However, it is expected to decline to 117.545 billion RMB by 2028, with a negative CAGR of -3.82% [10]. - The industry is witnessing a shift from rare diseases to chronic diseases and tumors, with significant advancements in technology and delivery systems, including AI-assisted design and liver-targeted delivery [34][36][38]. Market Background - Nucleic acid drugs are defined as drugs that utilize nucleic acids to intervene in disease by regulating gene expression. They have shown potential in treating metabolic diseases, genetic disorders, and cancers [6]. - The exploration of nucleic acid drugs began in 1978, with the first commercial product, Vitravene, launched in 1998. The market has since evolved, with significant developments in RNA therapies [7][8]. Market Status - The nucleic acid drug market is primarily focused on rare diseases but is gradually expanding to common diseases. The demand for treatment is urgent due to the high prevalence of rare diseases, with over 7,000 known globally [15]. - Capital investment in the nucleic acid sector has increased, with 23 financing events reported in 2024, totaling nearly 3 billion RMB. This funding supports the development of innovative drug delivery systems and clinical trials [12]. Market Competition - The competitive landscape features a tiered structure, with leading companies such as Saint No Biopharma and Hegia Biopharma in the first tier, followed by companies like Rebio and Haobo Pharmaceutical in the second tier [19][20]. - The report highlights ten recommended brands in the nucleic acid drug space, including Rebio, Watson Biopharma, and Saint No Biopharma, each with unique strengths and challenges in their product pipelines [22][23][24]. Development Trends - Technological breakthroughs in liver-targeted delivery and AI design are driving innovation in the nucleic acid drug industry, with expectations that over 50% of the pipeline will utilize these advancements by 2030 [34]. - The commercialization of nucleic acid drugs is accelerating through licensing agreements and healthcare payment reforms, enhancing drug accessibility and market growth [35]. - The industry is expanding its focus from rare diseases to chronic diseases and tumors, with significant research and clinical trials underway for conditions such as hypertension and Alzheimer's disease [38].